Business context and reporting period
India Globalization Capital, Inc. (IGC; NYSE American: IGC) filed this Form 10-K for the fiscal year ended March 31, 2018—not a standalone “2017 Q4” report. IGC was transitioning from infrastructure commodity trading and equipment rental toward cannabinoid-based alternative therapies. Legacy infrastructure generated all fiscal 2018 revenue; alternative therapies generated none.
Hyalolex, IGC’s lead Alzheimer’s-symptom product, was in production preparation, with commercialization through medical dispensaries expected in the second half of calendar 2018. Hyalolex and the other pipeline products are not FDA-approved pharmaceuticals.
Financial performance and position
| Metric | FY ended Mar. 31, 2018 | FY ended Mar. 31, 2017 |
|---|---|---|
| Revenue | $2.193 million | $580,372 |
| Gross profit / margin | $81,524 / approximately 3.7% | $218,237 / approximately 37.6% |
| SG&A | $1.870 million | $2.272 million |
| Operating loss | $1.789 million | $2.054 million |
| Net loss | $1.786 million | $1.853 million |
| Net loss per share, basic and diluted | $0.06 | $0.07 |
| Cash from operating activities | $(1.931) million | $(1.391) million |
| Cash from investing activities | $(657,113) | $(241,354) |
| Cash from financing activities | $3.715 million | $707,564 |
Revenue grew 277.8%, principally from higher infrastructure-material trading volumes. Cost of revenue rose faster than sales, reducing gross profit despite the increase in revenue. Management attributed the lower operating loss mainly to reduced depreciation and SG&A; the prior-year result also included substantial one-time non-cash other income.
At March 31, 2018, cash and cash equivalents were $1.658 million, working capital was $858,993, total assets were $10.853 million, and total liabilities were $2.788 million. Current liabilities included a $1.8 million note payable reclassified from non-current liabilities. Other loans totaled $427,500, including related-party borrowings. Management described non-GAAP cash burn, adjusted for non-cash items, as approximately $1.3 million and said cash on hand was adequate for obligations; it also said additional capital would be needed to initiate medical trials.
Operating cash outflow exceeded net loss, with working-capital movements and Hyalolex work-in-progress inventory contributing. Financing cash inflow was mainly from equity sales: approximately $3.740 million gross proceeds, before issuance costs. The filing reports 30.764 million shares outstanding at fiscal year-end and 31.028 million as of June 15, 2018.
Material changes versus the prior year
- Revenue rose from $580,372 to $2.193 million, but gross profit fell from $218,237 to $81,524.
- Net loss narrowed modestly, from $1.853 million to $1.786 million; operating cash use increased from $1.391 million to $1.931 million.
- Hyalolex work-in-progress inventory increased to $486,497 from zero, and patent-related intangible assets were reported at $127,826.
- Net property, plant and equipment rose to $6.237 million, largely because approximately $5.175 million of land was reclassified from investments. This is primarily a reclassification, not equivalent to new operating capacity.
- IGC exited its Malaysian real-estate business and classified Cabaran Ultima as held for sale at $147,500. It also sold its Brilliant Hallmark investment, with the returned shares retired.
- Total liabilities declined from $3.934 million to $2.788 million, although the $1.8 million note became current. Equity proceeds supported the increase in cash.
Outlook, risks, contingencies and unusual items
- Management’s fiscal 2019 plan for legacy infrastructure was to maintain annual revenue of $3–$5 million and seek better margins through lower financing costs and modest equipment investment. Hyalolex commercialization was anticipated in the second half of calendar 2018, subject to state licensing, manufacturing and other requirements.
- Management said trial initiation would require additional capital. The company had an ATM program and, after year-end, a $30 million Form S-3 registration statement became effective. Further equity financing could dilute shareholders; management also cited difficulty accessing banking and capital markets because of the company’s perceived cannabis-industry association.
- Cannabis remains illegal under U.S. federal law, despite state medical-cannabis programs. The filing discusses uncertainty following rescission of the Cole Memo in January 2018, alongside a federal budget provision restricting certain Justice Department enforcement against state-compliant medical-cannabis activity. Regulatory or policy changes could impede product development, sales, financing or listing status.
- IGC relies on licensed third parties for Hyalolex manufacturing and distribution and does not have its own manufacturing license or facilities for the product. Product claims are not FDA-approved; the filing identifies patent registration, regulatory compliance, competition, supply relationships, cybersecurity, foreign exchange and access to capital as risks.
- A $1.8 million Bricoleur Partners note remained disputed. IGC had issued shares over time in connection with the loan and asserted that those issuances substantially repaid debt; in May 2018 it sued seeking a declaratory judgment and damages. The outcome was unresolved.
- Accounts receivable included aged Cochin International Airport arbitration receivables of $428,969, outstanding for more than a year and carried without impairment. Management expected collection, but timing depended on further proceedings. Elsewhere, MD&A describes an awarded construction-claim receivable of approximately $470,000; the filing does not clearly reconcile these amounts.
- Other notable items include $576,251 of share-based compensation in the cash-flow reconciliation, related-party loans and facility payments, and an auditor change. Management assessed internal controls as effective; the 2018 financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Whether Hyalolex secured required state approvals, licensed manufacturing and distribution partners, and actual commercial sales after the stated launch expectation.
- How much additional financing is required for trials and commercialization, and the potential dilution from the ATM, S-3 and other securities.
- The status and terms of the Bricoleur dispute, including the principal balance, treatment of prior share issuances and any subsequent resolution.
- Collectability and timing of the aged airport arbitration receivable; reconcile the approximately $428,969 and $470,000 figures disclosed in different sections.
- Independent support for the $5.175 million land valuation and the $147,500 held-for-sale valuation, and whether planned monetizations occurred.
- Whether the sharp year-over-year gross-margin decline reflects transaction mix, pricing or other persistent economics in the legacy business.